Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab-based therapies in newly diagnosed systemic AL amyloidosis
2023-507069-25-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of daratumumab in light-chain amyloidosis (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of any toxicity grade of cardiac events and Daratumumab trough concentration. Started Nov 2023; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2023-507069-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507069-25-00.